Briefing: Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial

Strategic angle: Lilly is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and its upcoming pill, orforglipron.